You are here

Our science / Clinical Trials / Find a Trial / NCT00383253

Methods Study to Characterize Early Indicators of Weight Loss in People

Back to Search Print Save as PDF Bookmark Trial

NCT00383253

Last updated on November 12, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Adelaide, South Australia, 5000 Australia
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obesity
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects >=18 years of age with BMI >= 30 and

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Females, those with illnesses expected to cause weight loss, those without stable body
weight within 3 months of screening.

NCT00383253
Pfizer
Completed
Methods Study to Characterize Early Indicators of Weight Loss in People

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search
Descriptive Information
Brief Title  ICMJE Methods Study to Characterize Early Indicators of Weight Loss in People
Official Title  ICMJE A Randomized, Open-Label, Parallel Group, Fixed Energy Deficit Methodology Trial to Characterize Early Efficacy Biomarkers During Treatment of Obesity in Adult, Obese, Male Subjects.
Brief SummaryMethods study to characterize early indicators of weight loss in people.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Obesity
Intervention  ICMJE
  • Behavioral: caloric restriction - 10%
    Subjects maintained on 10% caloric restriction (caloric intake = 90% of baseline)
  • Behavioral: caloric restriction - 25%
    Subjects maintained on 25% caloric restriction (caloric intake = 75% of baseline)
  • Behavioral: caloric restriction - 50%
    Subjects maintained on 50% caloric restriction (caloric intake = 50% of baseline)
  • Behavioral: caloric restriction - Control
    Subjects maintained on their baseline caloric intake (caloric restriction = none)
Study Arms  ICMJE
  • Experimental: 10%
    Intervention: Behavioral: caloric restriction - 10%
  • Experimental: 25%
    Intervention: Behavioral: caloric restriction - 25%
  • Experimental: 50%
    Intervention: Behavioral: caloric restriction - 50%
  • Placebo Comparator: Control
    Intervention: Behavioral: caloric restriction - Control
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 20, 2009)		57
Original Enrollment  ICMJE
 (submitted: October 2, 2006)		48
Actual Study Completion Date  ICMJE March 2008
Primary Completion DateNot Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects >=18 years of age with BMI >= 30 and < 40 kg/m2

Exclusion Criteria:

  • Females, those with illnesses expected to cause weight loss, those without stable body weight within 3 months of screening.
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00383253
Other Study ID Numbers  ICMJE A9001342
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyDirector, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE
  • University of Adelaide
  • Royal Adelaide Hospital
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateMarch 2009

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now